Medication leaflets

Active substance

Results for the substance venetoclax

5 results

About this active substance

Venetoclax is a medication used for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic cancers, such as mantle cell lymphoma. It is a selective inhibitor of the BCL-2 protein, which helps cancer cells survive by preventing apoptosis (programmed cell death). By blocking BCL-2, venetoclax induces cancer cell death and reduces disease progression.

Venetoclax is administered orally, usually once daily, and the dosage is gradually increased during the first weeks of treatment to reduce the risk of tumor lysis syndrome, a serious complication associated with the rapid destruction of tumor cells.

Common side effects include nausea, diarrhea, fatigue, infections, and low blood cell counts. In rare cases, severe adverse reactions such as tumor lysis syndrome or serious infections may occur.

Venetoclax represents an innovative therapeutic option for patients with CLL and other hematologic cancers, helping to improve survival rates and reduce disease symptoms.